公开(公告)号：US11834409B2

公开(公告)日：2023-12-05

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Makoto Kamata ,  Yuya Oguro ,  Masataka Murakami ,  Minoru Nakamura ,  Fumie Yamaguchi ,  Takafumi Yukawa

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US08933069B2

公开(公告)日：2015-01-13

申请号：US14223329

申请日：2014-03-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Misaki Homma ,  Yuya Oguro

IPC: A61K31/00 ,  C07D495/04 ,  C07D498/20

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  C07D495/04 ,  C07D498/20

Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer.The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Abstract translation: 提供一种可用于预防或治疗癌症的化合物。 本发明涉及由式（I）表示的化合物：其中式中的每个符号如本说明书中所定义，或其盐或其前药，其可用于预防或治疗癌症。

公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US10323026B2

公开(公告)日：2019-06-18

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki Sugiyama ,  Jumpei Aida ,  Hidekazu Tokuhara ,  Tomohiro Okawa ,  Yuya Oguro ,  Minoru Nakamura ,  Masataka Murakami

IPC: C07D413/14 ,  C07D401/08 ,  C07D405/14 ,  C07D413/08 ,  C07D401/06 ,  C07D413/06

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09655900B2

公开(公告)日：2017-05-23

申请号：US15176893

申请日：2016-06-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Misaki Homma ,  Toru Miyazaki ,  Yuya Oguro ,  Osamu Kurasawa

IPC: A61K31/519 ,  C07D495/04 ,  C07D498/20 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  C07D495/04 ,  C07D498/20

Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer.The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US10131653B2

公开(公告)日：2018-11-20

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku Kamei ,  Yasuyoshi Arikawa ,  Tomohiro Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Takashi Miki ,  Jinichi Yonemori ,  Yuya Oguro ,  Takahiro Sugimoto ,  Masaki Seto ,  Goushi Nishida ,  Makoto Kamata ,  Hiroshi Imoto

IPC: C07D413/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/553

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11827601B2

公开(公告)日：2023-11-28

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Makoto Kamata ,  Yuya Oguro

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US11746109B2

公开(公告)日：2023-09-05

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro Iwata ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Misaki Homma ,  Yuya Oguro ,  Naohiro Taya ,  Lei Zhu ,  John Daniel Bailey ,  Marianne Langston ,  Siddhesh Dinanath Patil ,  Shruti Gour ,  Lilly Roy

IPC: C07D471/08 ,  A61K9/48

CPC classification number: C07D471/08 ,  A61K9/485 ,  A61K9/4858 ,  C07B2200/13

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.